Related Experiment Video

Updated: Apr 18, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.3K

Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance

Wen-Shuo Wu1, Yuh-Min Chen2

  • 1Department of Chest Medicine, Taipei Veteran General Hospital, Yang-Min National University, No. 21, Sec. 2, Shi-Pai Rd., Taipei 11217, Taiwan. marco1215@gmail.com.

Journal of Personalized Medicine
|January 8, 2015
PubMed

Insights

Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is common in non-small cell lung cancer (NSCLC). This review examines EGFR-TKI re-treatment strategies and the efficacy of different EGFR-TKI generations for resistant NSCLC.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are standard treatment for EGFR-mutated non-small cell lung cancer (NSCLC).
  • Acquired resistance, particularly the T790M mutation, frequently develops after EGFR-TKI treatment in NSCLC patients.
  • No established standard treatment exists for patients with acquired resistance to EGFR-TKIs.

Purpose of the Study:

  • To review current EGFR-TKI re-treatment strategies for NSCLC.
  • To evaluate the efficacy of various EGFR-TKI generations in patients with acquired resistance.

Main Methods:

  • Literature review of studies on EGFR-TKI re-treatment in NSCLC.
  • Analysis of clinical trial data and case reports regarding EGFR-TKI efficacy in resistant NSCLC.

Main Results:

  • The T790M mutation is the most common cause of acquired resistance to EGFR-TKIs in NSCLC.
  • Different generations of EGFR-TKIs show varying efficacy in overcoming acquired resistance.
  • Re-treatment strategies are being developed to manage resistant NSCLC.

Conclusions:

  • Effective strategies are needed to manage acquired resistance to EGFR-TKIs in NSCLC.
  • Further research into novel re-treatment approaches and next-generation EGFR-TKIs is crucial.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.5K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.8K

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
72
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K